Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.


TSXV:MPH - Post by User

Bullboard Posts
Post by aristotle101on Dec 05, 2005 9:26am
178 Views
Post# 9945455

These are impressive results!!

These are impressive results!! Medicure Reports Positive Results From Phase II MEND-CABG Study MC-1 Demonstrates Statistically Significant Reduction in Post-CABG Heart Attacks The MEND-CABG Study Results: - 37.2% reduction in the composite of death, non-fatal myocardial infarction - 46.9% reduction in non-fatal myocardial infarction - 14.0% reduction in the primary endpoint composite of death, non-fatal myocardial infarction and non-fatal stroke versus placebo (p equals 0.312). -78.7% reduction in physician diagnosed myocardial infarctions results to accelerate our ongoing discussions with potential partners From businesswire. Impressive! Hang tight!!! Aristotle101
Bullboard Posts